Advances and Challenges in the Management of Myelodysplastic Syndromes
Open Access
Abstract
Myelodysplastic syndromes/neoplasms (MDS) represent a biologically and clinically diverse group of myeloid malignancies marked by cytopenias, morphological dysplasia, and an inherent risk of progression to acute myeloid leukemia. Over the past two decades, the field has made significant advances in characterizing the molecular landscape of MDS, leading to refined classification systems to reflect the underlying genetic and biological diversity. In 2025, the treatment of MDS is increasingly individualized, guided by integrated clinical, cytogenetic, and molecular risk stratification tools. For lower-risk MDS, the treatment paradigm has evolved beyond erythropoiesis-stimulating agents (ESAs) with the introduction of novel effective agents such as luspatercept and imetelstat, as well as shortened schedules of hypomethylating agents (HMAs). For higher-risk disease, monotherapy with HMAs continue to be the standard of care as combination therapies of HMAs with novel agents have, to date, failed to redefine treatment paradigms. The recognition of precursor states like clonal hematopoiesis of indeterminate potential (CHIP) and the increasing use of molecular monitoring will hopefully enable earlier intervention/prevention strategies. This review provides a comprehensive overview of the current treatment approach for MDS, highlighting new classifications, prognostic tools, evolving therapeutic options, and ongoing challenges. We discuss evidence-based recommendations, treatment sequencing, and emerging clinical trials, with a focus on translating biological insights into improved outcomes for patients with MDS.Keywords
This publication has 125 references indexed in Scilit:
- Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS TrialAdvances in Therapy, 2025
- Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysisHemaSphere, 2024
- Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromesAmerican Journal of Hematology, 2023
- Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort studyCancer, 2023
- A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromesAmerican Journal of Hematology, 2022
- The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinionAnnals of Hematology, 2019
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic SyndromesTransplantation and Cellular Therapy, 2018
- Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center ExperienceTransplantation and Cellular Therapy, 2018
- Epidemiology of Myelodysplastic SyndromesThe American Journal of Medicine, 2012
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006